ETOPOSIDE, DOXORUBICIN AND CISPLATIN (EAP) TREATMENT IN ADVANCED GASTRIC-CARCINOMA - A MULTICENTER STUDY OF THE ITALIAN TRIALS IN MEDICAL ONCOLOGY (ITMO) GROUP

被引:17
作者
BAJETTA, E
DIBARTOLOMEO, M
DEBRAUD, F
BOZZETTI, F
BOCHICCHIO, AM
COMELLA, P
FAGNANI, D
FARINA, G
FERRONI, C
FRANCHI, R
GEBBIA, V
IANNIELLO, G
IIRILLO, A
PINOTTI, G
SCHIEPPATI, G
UCCI, G
VISINI, M
ZANIBONI, A
BUZZONI, R
CASARTELLI, C
NELLI, P
机构
[1] Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan
关键词
GASTRIC CANCER; ETOPOSIDE; DOXORUBICIN; CISPLATIN COMBINATION; CHEMOTHERAPY;
D O I
10.1016/0959-8049(94)90527-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Various reports have documented the efficacy of the combination of etoposide, doxorubicin and cisplatin (EAP) in the treatment of advanced gastric cancer, although other studies have not confirmed such results. This multicentre phase II study was designed to try to define the efficacy and tolerability of the original EAP regimen. From January 1990 to May 1992, 96 patients with locally advanced or metastatic gastric cancer were treated every 3 weeks with etoposide (120 mg/m(2)) on days 4, 5 and 6, doxorubicin (20 mg/m(2)) on days 1 and 7, and cisplatin (40 mg/m(2)) on days 2 and 8. All of the patients had measurable lesions, and were to receive a maximum of six cycles. A total of 416 courses was given (median four/patient), 27% with a delay of greater than or equal to 2 weeks. Objective responses were achieved in 34 of the 91 evaluable patients (37%: confidence interval 27-47%), with complete response (CR) in 11 (12%) and partial response (PR) in 23 (25%). The median duration of response was 6 months (range 1-19), and the median survival of the 96 eligible patients was 9 months. Side-effects (WHO grade 3-4) were leucopenia (30%), thrombocytopenia (9%) and mucositis (10%). We conclude that the EAP regimen is active in inducing major objective responses (12% of CR), and that treatment is feasible in patients with good performance status.
引用
收藏
页码:596 / 600
页数:5
相关论文
共 30 条
[1]   INTENSIVE PREOPERATIVE CHEMOTHERAPY WITH COLONY-STIMULATING FACTOR FOR RESECTABLE ADENOCARCINOMA OF THE ESOPHAGUS OR GASTROESOPHAGEAL JUNCTION [J].
AJANI, JA ;
ROTH, JA ;
RYAN, MB ;
PUTNAM, JB ;
PAZDUR, R ;
LEVIN, B ;
GUTTERMAN, JU ;
MCMURTREY, M .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (01) :22-28
[2]  
CAZAP EL, 1986, CANCER TREAT REP, V70, P781
[3]  
DUCREUX M, 1993, P AM SOC CLIN ONCOL, P12
[4]  
ELLIOTT TE, 1990, CANCER, V65, P1491, DOI 10.1002/1097-0142(19900401)65:7<1491::AID-CNCR2820650707>3.0.CO
[5]  
2-G
[6]  
GUNZEL K, 1991, CANCER THERAPY CONTR, V1, P327
[7]  
HAIM N, 1992, ANN ONCOL, V2, P310
[8]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[9]   PHASE-II TRIAL OF ETOPOSIDE (V), ADRIAMYCIN (A), AND CISPLATINUM (P) IN PATIENTS WITH METASTATIC GASTRIC-CANCER [J].
KATZ, A ;
GANSL, RC ;
SIMON, SD ;
GAMARODRIGUES, J ;
WAITZBERG, D ;
BRESCIANI, CJC ;
PINOTTI, HW .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1991, 14 (04) :357-358
[10]   FAMTX VERSUS ETOPOSIDE, DOXORUBICIN, AND CISPLATIN - A RANDOM ASSIGNMENT TRIAL IN GASTRIC-CANCER [J].
KELSEN, D ;
ATIQ, OT ;
SALTZ, L ;
NIEDZWIECKI, D ;
GINN, D ;
CHAPMAN, D ;
HEELAN, R ;
LIGHTDALE, C ;
VINCIGUERRA, V ;
BRENNAN, M .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :541-548